Development of ginger oleoresin-enriched marshmallow candy as a nutraceutical for managing pediatric chemotherapy-induced nausea and vomiting

Chemotherapy-induced nausea and vomiting (CINV) significantly impact pediatric cancer patients, affecting treatment adherence and quality of life. This study aimed to develop gingerol-enriched marshmallow candy as a nutraceutical to alleviate CINV, offering a palatable and effective antiemetic formulation for children. A central composite experimental design was employed to optimize the formulation. The various parameters, including textural attributes (hardness, springiness, and cohesiveness), weight variation, disintegration time, in vitro release, moisture content, water activity coefficient, and stability, of the marshmallows were evaluated to ensure the efficacy and quality of the product. The study identified an optimal formulation comprising ginger powder extract (4% w/w), gelatin (6% w/w), gum acacia (2.5% w/w), and agar (2.5% w/w). This composition demonstrated excellent textural characteristics, rapid disintegration, and efficient gingerol release in simulated conditions. The marshmallow candy also exhibited high acceptability in terms of stability and potential usability as a pediatric nutraceutical. The ginger oleoresin-enriched marshmallow candy presents a novel and appealing delivery system for managing CINV in pediatric patients. Its favorable sensory and functional properties could improve compliance and enhance the overall treatment experience for children undergoing chemotherapy.